BCG
RXRX icon

Breakwater Capital Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Breakwater Capital Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Sell
10,089
-7,383
-42% -$24.6K ﹤0.01% 376
2026
Q1 		$53.6K Sell
17,472
-2,225
-11% -$8.6K 0.01% 373
2025
Q4 		$80.6K Buy
+19,697
New +$97.6K 0.01% 352

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Breakwater Capital Group's RXRX Position: Q2 2026 in Review

Breakwater Capital Group reduced its Recursion Pharmaceuticals (RXRX) stake by 42% in Q2 2026, selling an estimated $24.6K and leaving 10,089 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #376.

Breakwater Capital Group first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $80.6K in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Breakwater Capital Group held 10,089 shares of Recursion Pharmaceuticals worth $37K as of Q2 2026.
  • Breakwater Capital Group sold 7,383 Recursion Pharmaceuticals shares in Q2 2026, an estimated $24.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Breakwater Capital Group's portfolio in Q2 2026, its #376 holding.
  • Breakwater Capital Group first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Breakwater Capital Group's Recursion Pharmaceuticals position peaked at $80.6K in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Breakwater Capital Group's 13F filing for Q2 2026, filed 8 Jul 2026.